U.S. Markets closed

Don’t Overlook Biotech IPOs Amidst the Tech Mania

Josh Nathan-Kazis

Early-stage biotech companies that have gone public have, on average, raised more money and performed better than biotech companies whose initial public offering came closer to when they brought a product to market.